Passage Bio assumed with an Outperform at Wedbush

TipRanks

Sat, Nov 30, 2024, 4:55 AM 1 min read

Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage’s upsized IPO, but the current valuation looks to be a “deep discount” compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors.